Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease.
BMC Nephrol
; 25(1): 97, 2024 Mar 15.
Article
in En
| MEDLINE
| ID: mdl-38491453
ABSTRACT
BACKGROUND:
In this study, we aimed to clarify the beneficial effects of urate-lowering treatment with the novel agent dotinurad on renal function in patients with chronic kidney disease (CKD) and hyperuricemia (HUA).METHODS:
Thirty-five patients with CKD (mean age 65.4 ± 14.8 years, 23 men) diagnosed with HUA were recruited. Changes in eGFR before and after dotinurad administration were assessed. Patients first underwent a 3-month observation period and then 3 months treatment with dotinurad.RESULTS:
During the observation period, mean eGFR (mL/min/1.73 m2) declined significantly. The baseline eGFR was 31.8 ± 16.4 and the serum urate level (sUA, mg/dL) was 8.1 ± 1.7. During the treatment period, eGFR recovered to 36.5 ± 17.5 and sUA decreased to 6.7 ± 1.0. The increase in eGFR after dotinurad administration was correlated with a decrease in sUA (R = 0.375, p = 0.0263).CONCLUSION:
Dotinurad administration to patients with CKD and HUA appears to be beneficial in restoring kidney function. Dotinurad may represent a potential medication for the prevention of kidney function decline caused by HUA.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hyperuricemia
/
Renal Insufficiency
/
Renal Insufficiency, Chronic
/
Benzothiazoles
Limits:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
BMC Nephrol
Journal subject:
NEFROLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Japón